News
-
5 October 2006
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today that it has successfully raised EUR 10 million with an option to call another EUR 5 million (in total CHF 24 million) in a private financing round. The oversubscribed funding was led by NGN Capital, one of Santhera's largest current shareholders. New investors in the round include NeoMed Management (Jersey), two equity funds managed by Schroder Investment Management (Luxembourg) SA and BioMedinvest (Switzerland). In addition, existing investors NGN Capital, Carnegie Asset Management, GIMV, Dow Chemical, Clariden Biotechnology Fund, 3i and private investors supported this round of financing.
-
24 July 2006
Endosense, an emerging cardiovascular device com- pany developing the TacticathTM, a unique Force Sensor ablation catheter for use in the field of atrial fibrillation, today announced the appointment of Lawrence Kinet as Chairman of the Board. Mr Kinet was previously a Group Managing Director of Smiths Group PLC and President of Smiths Medical, a major supplier of single-use medical devices used during critical and intensive care procedures with worldwide sales of approximately $1.3 billion.
-
21 November 2005
Endosense, an emerging cardiovascular device company, today announced the closing of a CHF 26 million (USD 20 million) financing with 3i and NeoMed. Endosense, set up in 2003, is developing a Force Sensor ablation catheter for use in the field of cardiac arrhythmia.
-
6 November 2005
Subsidiaries of Baxter International Inc. and Kuros Biosurgery AG announced that they have signed an agreement under which Kuros has granted Baxter exclusive worldwide rights to develop and commercialize a portfolio of hard and soft tissue-repair products. These products will be based on Baxter’s fibrin-based biomatrix, TISSEEL® Fibrin Sealant, combined with Kuros’ proprietary biologics and associated binding technology.
-
6 October 2005
Kuros Biosurgery AG is pleased to announce that the Company has raised CHF 5.6m in additional venture capital funding, fully subscribed by the Company’s existing investors (Venture Incubator, NeoMed Management, CDC Entreprises, Genevest Consulting Group, Vinci Capital and DEFI Gestion) and some of the Company’s employees.
